Benefits
Blood pressure reduction (extensive trial evidence)
Multiple Kyolic® clinical trials and meta-analyses document blood pressure reduction in adults with elevated BP — reductions of roughly 5 to 10 mmHg systolic in people who already have hypertension. A 2016 meta-analysis of 20 controlled trials in 970 people found an average of 5.1 mmHg systolic and 2.5 mmHg diastolic overall, rising to about 8.7 mmHg systolic in those with hypertension, so the larger single-trial numbers are the top of the range rather than the typical result. In the Australian trial, people whose systolic pressure was already below 140 mmHg showed no significant change. Most of this evidence comes from one research group in Australia, in people already taking prescribed blood pressure medication, using product supplied by the manufacturer, although a separate Swedish trial also recorded systolic pressure falling from 148 to 140 mmHg over a year.
Arterial calcification progression slowing
Four one-year randomized trials using repeat coronary CT scans reported slower progression of coronary artery calcium or of low-attenuation plaque compared with placebo. Their size is the thing to hold on to: 19 completers in the 2004 study, which called itself a small pilot, 65 in the 2009 trial that combined the extract with B vitamins, folate and arginine so the garlic contribution cannot be separated out, 55 in a 2016 metabolic syndrome trial, and 104 in a 2020 Swedish trial. A calcium score is a picture of an artery, not a heart attack or a stroke, and no trial has tested whether this extract changes those outcomes. All four were funded by the manufacturer or used product it supplied.
Cholesterol: mixed, and null in the largest trial
This is the weakest cardiovascular claim on the page. The biggest and longest test, a six-month trial at Stanford in 192 adults with LDL cholesterol between 130 and 190 mg/dL, gave aged garlic extract, raw garlic, powdered garlic or placebo and found no significant effect of any of them on LDL, HDL, triglycerides or the cholesterol ratio. The 2004 coronary calcium study likewise found no significant difference in any individual cholesterol measure. Older and smaller work points the other way: a crossover trial in 41 men taking 7.2 g a day, several times the usual supplement dose, reported total cholesterol about 6 percent lower and LDL about 5 percent lower than placebo, and pooled analyses of garlic in general report small reductions in people with mildly raised cholesterol. The honest summary is that the effect is inconsistent and absent in the most rigorous trial, so lowering cholesterol is not a good reason to choose this product.
Endothelial function and arterial elasticity
The results here are mixed and the trials are very small. A crossover study in 15 men with coronary artery disease found flow-mediated dilation, a measure of how well an artery relaxes, improved by 44 percent over two weeks of the extract, and the GarGIC trial in 49 people with hypertension found lower central blood pressure and lower arterial stiffness. Against that, a crossover trial in 26 adults with type 2 diabetes found no effect on endothelial function at all. The proposed mechanism is support of the nitric oxide pathway and reduced vascular oxidative stress, but both trials that measured oxidative stress markers alongside these outcomes found no change in them, so the second half of that mechanism is not confirmed in people.
Immune system support
One 90-day randomized trial in 120 healthy adults taking 2.56 g a day found better proliferation of natural killer cells and gamma delta T cells at 45 days, and at 90 days a 21 percent lower cold and flu symptom score, 61 percent fewer days functioning below normal and 58 percent fewer missed days of work or school. Read the direction carefully: the number of people who caught a cold or flu did not differ between the groups. What changed was how bad and how long the illness was, not whether it happened. The natural killer cell finding has appeared in two other small trials, one in 50 patients with advanced cancer in Japan and one in 51 adults with obesity, but the cold and flu result itself has never been repeated, that trial was co-funded by the manufacturer, and a 2014 Cochrane review of garlic for the common cold concluded the overall trial evidence is insufficient. This is much thinner than the blood pressure evidence.
What the research base actually contains
A count of papers is not something you can feel, so here is what the count actually contains. As of August 2026, PubMed indexes 386 records for aged garlic extract and 20 that name Kyolic. The manufacturer cites a figure above 850, which sweeps in laboratory and animal studies, conference abstracts and publications that are not indexed at all. Randomized trials in people are a much smaller slice: PubMed tags 38 records as randomized controlled trials, most of them enrolling fewer than 120 people, and the ones with positive results were largely funded by the manufacturer or used product it supplied. Research volume is not the same as research strength, and this page rates the strength rather than the volume.
Reproducible SAC standardization
Kyolic® provides consistent S-allyl cysteine content batch-to-batch through the controlled proprietary aging process. Consistent standardization is what makes it possible for one research group to repeat another group's trial, and that is a genuine advantage over unstandardized garlic products. It is a manufacturing property rather than a health effect, though, and the amount of S-allyl cysteine actually delivered still varied between the trials on this page, from about 1.2 mg to 2.4 mg a day.
Odorless formulation (a convenience, not a health effect)
The aging process converts the pungent sulfur compounds responsible for garlic breath into odorless water-soluble ones, so this form is close to odorless, and it was tolerated well in trials running from 12 weeks up to a year. That is a real practical reason people manage to keep taking it. It is a property of the formulation rather than an effect on health, and it should not be counted as evidence that the product works.
Mechanism of action
S-allyl cysteine bioavailability
Kyolic®'s 20+ month aging process converts the unstable thiosulfinates of raw garlic and its gamma-glutamyl-S-allylcysteine precursor into stable, water-soluble S-allyl cysteine (SAC). One correction worth making: SAC is not formed from allicin, which is itself unstable and breaks down into other compounds. SAC is well absorbed and produces reproducible blood levels, which is why the trials use it as a marker of whether participants actually took their capsules. Good absorption of a marker compound is not, by itself, evidence that any health outcome changes.
Cardiovascular pathway support
Kyolic® components support nitric oxide pathway, reduce vascular oxidative stress, modulate platelet aggregation, and improve endothelial function. Most of these are proposed mechanisms drawn from laboratory and animal work; the exception is the effect on platelet aggregation, which has been measured directly in people and is also the basis for the bleeding caution in the safety section. The human trials measured outcomes such as blood pressure and coronary calcium scores, and none of them established which of these pathways, if any, is doing the work.
Antioxidant capacity enhancement
Aged garlic extract has significantly higher antioxidant capacity than raw garlic — the aging process concentrates polyphenols and Maillard reaction products with antioxidant activity. This is a laboratory measurement made on the extract itself, and it has not carried through into people. The two placebo-controlled trials that measured antioxidant status and oxidative stress directly in humans swallowing the extract, one in 26 adults with type 2 diabetes and one in 15 men with coronary artery disease, both found no significant change. Older work is weaker and mixed: a seven-day study reported that LDL taken from supplemented people resisted oxidation better in a test tube, which is again a laboratory measurement rather than a health outcome. Higher antioxidant capacity in a test tube is not the same thing as lower oxidative stress in a person, which is why this page no longer carries an antioxidant category.
Clinical trials
Two double-blind randomized placebo-controlled trials of Kyolic aged garlic extract in adults whose blood pressure stayed high despite medication. Ried 2010 (Maturitas) gave 960 mg a day providing 2.4 mg S-allyl cysteine for 12 weeks. The GarGIC trial (Front Nutr 2018) gave 1.2 g a day providing 1.2 mg S-allyl cysteine for 12 weeks.
Ried 2010: 50 adults in Australian general practice whose records showed treated but uncontrolled hypertension. GarGIC 2018: 49 adults with uncontrolled hypertension who completed the trial. Both are small, both enrolled a diagnosed disease under medical care with the extract added on top of prescribed drugs, both came from the same research group, and both used product supplied by the manufacturer.
In Ried 2010, systolic blood pressure averaged 10.2 mmHg lower than placebo over 12 weeks among the 50 participants who started at 140 mmHg or above; in those already below 140 mmHg, the difference was not significant. In GarGIC, blood pressure among the 49 participants with uncontrolled hypertension fell 10 mmHg systolic and 5.4 mmHg diastolic against placebo, with lower arterial stiffness and a shift in gut bacteria. The limits that matter: both trials enrolled fewer than 60 people, both were adjuncts to prescribed antihypertensive drugs rather than replacements, neither ran long enough to see a heart attack or a stroke, and the wider 2016 meta-analysis of 20 trials found a smaller average effect of 5.1 mmHg systolic.
Four randomized double-blind placebo-controlled trials, each roughly a year long, used repeat CT scanning to measure change in coronary artery calcium or plaque: Budoff 2004 (4 mL a day added to statin therapy), Budoff 2009 (250 mg a day combined with vitamin B12, folic acid, vitamin B6 and L-arginine), Matsumoto 2016 (2,400 mg a day) and Wlosinska 2020 (2,400 mg a day).
Budoff 2004: 23 patients on statin therapy enrolled, 19 completed. Budoff 2009: 65 patients at intermediate cardiovascular risk, average age 60, 79 percent male. Matsumoto 2016: 55 patients with metabolic syndrome, average age 59, 71 percent male. Wlosinska 2020: 104 patients at increased cardiovascular risk in Sweden. All four are patient populations under medical care, not healthy adults, and all four were manufacturer funded or manufacturer supplied.
Budoff 2004 reported calcium scores rising 7.5 percent in the extract group against 22.2 percent on placebo over a year, and described itself as a small pilot study. Budoff 2009 reported slower calcium progression and better vascular reactivity, but the capsule combined the extract with B vitamins, folate and arginine, so no part of the result can be attributed to garlic on its own. Matsumoto 2016 found less low-attenuation plaque but no significant difference in total plaque volume, non-calcified plaque or dense calcium. Wlosinska 2020 reported slower calcium progression along with lower interleukin-6 and blood glucose. What none of them show: a calcium score is an imaging marker, not a clinical event, and no trial has tested whether this extract prevents heart attacks, strokes or deaths. Budoff 2004 also found no significant difference in any individual cholesterol measure.
Randomized, double-blind, placebo-controlled trial of aged garlic extract at 2.56 g a day for 90 days, with immune cell measurements at 45 days and daily self-reported illness diaries through the cold and flu season (Clinical Nutrition, 2012; registered as NCT01390116).
120 healthy adults aged 21 to 50 at a United States university, 60 per group. Note that these were healthy volunteers rather than patients, which is unusual on this page, and that the trial was co-funded by the manufacturer, which also supplied the capsules.
At 45 days, natural killer cells and gamma delta T cells from the supplemented group proliferated better than those from the placebo group. Over the 90 days, that group reported a 21 percent lower cold and flu symptom score, 61 percent fewer days functioning below normal and 58 percent fewer missed days of work or school. The direction that matters most: the number of cold and flu episodes did not differ between groups, so this trial supports milder and shorter illness rather than fewer illnesses. The natural killer cell result has been seen by other groups, including a 50-person Japanese trial in advanced cancer, but the cold and flu finding has not been repeated, and a 2014 Cochrane review of garlic for the common cold concluded the overall trial evidence is insufficient.